Trials / Completed
CompletedNCT00152048
Evaluation of Eflornithine on Facial and Forearm Skin
A 24 Week Randomised Double Blind Placebo Controlled Study to Evaluate the Atrophogenic Potential of Eflornithine in the Treatment of Women With Excessive Facial Hair
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 78 (planned)
- Sponsor
- Allergan · Industry
- Sex
- Female
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate whether regular use of eflornithine 11.5% cream in treating women with facial hair will induce skin damage (atrophy) on the face and/or forearms
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Eflornithine hydrochloride |
Timeline
- Start date
- 2004-11-30
- Completion
- 2005-10-31
- First posted
- 2005-09-09
- Last updated
- 2019-10-30
Source: ClinicalTrials.gov record NCT00152048. Inclusion in this directory is not an endorsement.